Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

122

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

September 30, 2011

Conditions

Metastatic Breast Cancer

Interventions

DRUG

bevacizumab

10mg/kg，Day1, 15 of 1 cycle(4 weeks)

DRUG

Paclitaxel

90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)

Trial Locations (5)

Kanto Region, Kanto

Kinki Region, Kinki

Kyushu region, Kyushu

Sikoku region, Sikoku

Tohoku region, Tōhoku